Wellbeing Subsidiary KGK Science Announces Successful Delivery of CBD and THC Through the Skin of Healthy Volunteers

Gefion Canada GT4 technology was used to deliver cannabidiol (CBD) and tetrahydrocannabinol (THC) to healthy volunteers in the form of a topical cream applied to the skin

VANCOUVER, British Columbia--()--Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announced today that its wholly owned subsidiary KGK Science Inc. (“KGK”), completed an open label study, where Gefion Canada (“Gefion”) GT4 technology was used to successfully deliver cannabidiol (CBD) and tetrahydrocannabinol (THC) to healthy volunteers in the form of a topical cream applied to the skin.

Gefion GT4 technology uses novel penetrating agents to transport CBD and THC through the skin and directly into the blood. Transdermal delivery of topically-applied cannabinoids can be difficult and prior to this study, published research demonstrating successful topical delivery did not exist. The Gefion Canada study, published in Advances in Therapy, showed for the first time that CBD and THC were successfully transported into the blood stream following application to the skin. Gefion GT4 technology may provide lower, more steady-state cannabinoid concentrations that minimize psychoactive effects in participants. These findings present a potential benefit in the treatment of chronic conditions over longer periods of time, or in the treatment of diseases where high concentrations of cannabinoids are needed in relation to the body weight of vulnerable populations such as pediatrics.

Importantly, CBD and THC delivery in this study was found to be safe and well tolerated by all participants. None of the volunteers experienced any intoxicating effects. Topical cannabis may provide the benefit of extended cannabinoid delivery without the worry of intoxication, suggesting it may be beneficial for certain lifestyles and therapeutic indications. However, more research is needed.

“This study represents an important step forward in cannabis research. This study opens the door for future double-blind, placebo-controlled trials to further investigate topical cannabis delivery,” says Dr. Erin D. Lewis, Scientific Director at KGK Science.

ABOUT GEFION

Gefion is a specialty pharmaceutical company whose mission is to utilize its technological, regulatory and commercial advantages to market cannabinoid prescription products in the United States, Canada and Europe focusing on established markets with predicate products and insurance reimbursement. It is developing GT4 CBD for the treatment of epilepsy in children.

ABOUT KGK SCIENCE

Subsidiary of Wellbeing Digital Sciences, KGK is a leading North American contract research organization based in London, Ontario that primarily provides high-quality clinical research trials with a focus on nutraceutical and emerging health care products. Founded in 1997, the business has successfully helped hundreds of companies with custom designed clinical trials and claim substantiation strategies to move products into global markets. KGK’s other existing service lines include expert regulatory support and compliance solutions, participant recruitment, research support services and consulting services. Furthermore, the company has produced over 150 publications, executed over 400 clinical trials across more than 40 indications, amassed 25,000 participants in its database and collected 10 million data points. For additional information, please visit kgkscience.com.

ABOUT WELLBEING DIGITAL SCIENCES

Wellbeing Digital Sciences Inc. is an evidence-based mental healthcare company focused on the development and implementation of innovative clinical treatment solutions, including psychedelic medicine and digital therapeutics, as supported by clinical research. Its mission is supported by a network of North American clinics that provide forward-thinking therapies and other types of treatment to patients as well as through a contract research organization that offers clinical trials services to clients pursuing drug development. For additional information, please visit wellbeingdigital.co.

On behalf of:
Najla Guthrie
Chief Executive Officer
WELLBEING DIGITAL SCIENCES

Notice Regarding Forward-Looking Information:

This news release contains forward-looking statements including but not limited to statements regarding the Company’s business, assets or investments, as well other statements that are not historical facts. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, investor interest in the business and prospects of the Company.

The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.

Contacts

Natalie Dolphin
VP of Marketing & Investment Relations
Email: ndolphin@wellbeingdigital.co
Twitter: @Wellbeing_IR

$Cashtags

Contacts

Natalie Dolphin
VP of Marketing & Investment Relations
Email: ndolphin@wellbeingdigital.co
Twitter: @Wellbeing_IR